EGFR and non-small cell lung carcinoma: In 133 NSCLC patients with EGFR-mutated adenocarcinoma and oligometastases, the addition of SBRT (n = 68) significantly improved survival when they also received tyrosine kinase inhibitor (TKI) compared to TKI alone.